Update on bioagent therapy in sarcoidosis

F1000 Medicine Reports

Volumn 2, Issue 1, 2010, Pages

  Cottin, Vincent ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; EVALUATION; HUMAN; LUNG FUNCTION; LUNG SARCOIDOSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SARCOIDOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77955073714     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M2-13     Document Type: Review

References (30)

1. Baughman RP, Costabel U, du Bois RM: Treatment of sarcoidosis. Clin Chest Med 2008, 29:533-48, ix-x.
2. Judson MA: An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999, 115:1158-65.
3. Baughman RP, Winget DB, Lower EE: Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000, 17:60-6.
4. Lower EE, Baughman RP: Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995, 155:846-51.
5. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, Schroeder DR: Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124:177-85. (Pubitemid 36851350)
6. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A: Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005, 128:1062-47.
7. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP: Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006, 100:2053-9.
8. Doty JD, Mazur JE, Judson MA: Treatment of sarcoidosis with infliximab. Chest 2005, 127:1064-71.
9. Stagaki E, Mountford WK, Lackland DT, Judson MA: The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009, 135:468-76.
10. Baughman RP, Bradley DA, Lower EE: Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005, 43:7-11.
11. Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller W Jr, Sands BE: A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:201-8. (Pubitemid 47596315)
12. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174:795-802.
13. Wells AU: Infliximab in extrapulmonary sarcoidosis: tantalising but inconclusive. Eur Respir J 2008, 31:1148-9.
14. Judson MA, Baughman RP, Costabel U, Flavin S, Lo KH, Kavuru MS, Drent M: Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008, 31:1189-96.
15. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-85.
16. Thielen AM, Barde C, Saurat JH, Laffitte E: Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology 2009, 219:59-62.
17. Marnane M, Lynch T, Scott J, Stack J, Kelly PJ: Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 2009, 256:139-40.
18. Massara A, Cavazzini L, La Corte R, Trotta F: Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 2010, 39:313-9.
19. Metyas SK, Tadros RM, Arkfeld DG: Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int 2009, 29:437-9.
20. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN: Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006, 25:596-7.
21. Almodovar R, Izquierdo M, Zarco P, Javier Quiros F, Mazzucchelli R, Steen B: Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2007, 25:99-101. (Pubitemid 46477494)
22. González-López MA, Blanco R, González-Vela MC, Fernández-Llaca H, Rodríguez-Valverde V: Development of sarcoidosis during etanercept therapy. Arthritis Rheum 2006, 55:817-20.
23. Ishiguro T, Takayanagi N, Kurashima K, Matsushita A, Harasawa K, Yoneda K, Tsuchiya N, Miyahara Y, Yamaguchi S, Yano R, Tokunaga D, Saito H, Ubukata M, Yanagisawa T, Sugita Y, Kawabata Y: Development of sarcoidosis during etanercept therapy. Intern Med 2008, 47:1021-5.
24. Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R: Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 2007, 26:1969-71.
25. Belkhou A, Younsi R, El Bouchti I, El Hassani S: Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine 2008, 75:511-2.
26. Wasfi YS, Rose CS, Murphy JR, Silveira LJ, Grutters JC, Inoue Y, Judson MA, Maier LA: A new tool to assess sarcoidosis severity. Chest 2006, 129:1234-45.
27. Brassard P, Kezouh A, Suissa S: Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006, 43:717-22.
28. Vultaggio A, Matucci A, Parronchi P, Rossi O, Palandri F, Romagnani S, Maggi E: Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol 2008, 21:367-74. (Pubitemid 351988399)
29. Miele E, Markowitz JE, Mamula P, Baldassano RN: Human anti-chimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004, 38:502-8.
30. van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H: An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008, 27:1021-8.